GlassScriptPhysician profile
Michael P Roberts
NPI 1972691368
$13,087.79
in general payments reported to CMS, 2019-2025
57 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $1,800 · 2021: $2,165 · 2022: $1,991 · 2023: $2,272 · 2024: $2,075 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,605 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,604.79 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,299.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,163.47 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $1,122.65 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,098.34 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $955.51 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $732.50 | 2019-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $714.80 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $498.27 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Teva Pharmaceuticals USA, INC. | $489.91 | 2019-2023 | Austedo |
| Pfizer INC. | $453.67 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $422.66 | 2020-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $414.83 | 2021-2025 | |
| Eisai INC. | $264.86 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $261.11 | 2019-2025 | |
| Amarin Pharma, INC. | $218.02 | 2019-2021 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $190.55 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.11 | 2022-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $182.97 | 2020-2024 | Xarelto |
| Allergan, INC. | $144.89 | 2020 | |
| Boston Scientific Corporation | $144.37 | 2024 | Watchman Flx |
| Grifols USA, LLC | $143.24 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.52 | 2019-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $126.91 | 2022 | |
| Melinta Therapeutics, LLC | $125.00 | 2023 | Kimyrsa |
| Acclarent, INC | $117.06 | 2023 | Acclarent Aera |
| Axsome Therapeutics, INC. | $101.10 | 2022-2025 | Auvelity |
| Abbott Laboratories | $99.43 | 2021-2025 | Freestyle Libre 3, Infinity |
| Exact Sciences Corporation | $91.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $91.64 | 2021-2024 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Dexcom, INC. | $88.28 | 2021-2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $86.19 | 2024 | Korlym |
| Otsuka America Pharmaceutical, INC. | $68.98 | 2023-2025 | Rexulti, Nuedexta |
| Arbor Pharmaceuticals, INC. | $63.74 | 2019-2020 | |
| Sanofi Pasteur INC. | $58.75 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $58.61 | 2021-2025 | Gvoke Hypopen |
| Opko Pharmaceuticals, LLC | $58.24 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.33 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $55.82 | 2024 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $54.88 | 2022-2023 | Crysvita |
| Mckesson Medical-Surgical, INC. | $50.14 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $42.54 | 2020-2025 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $42.31 | 2021 | |
| Upsher-Smith Laboratories LLC | $38.51 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $32.38 | 2025 | Gemtesa |
| Jazz Pharmaceuticals INC. | $29.99 | 2021 | |
| Seqirus USA INC | $26.83 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Alexion Pharmaceuticals, INC. | $24.75 | 2022 | |
| Lundbeck LLC | $19.91 | 2023 | Rexulti |
| Avanir Pharmaceuticals, INC. | $18.46 | 2022 | |
| Medtronic Minimed, INC. | $17.65 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.14 | 2019 | |
| Janssen Biotech, INC. | $17.10 | 2025 | Simponi Aria, Tremfya, Stelara |
| Bioventus LLC | $16.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.01 | 2019 | |
| Kaleo, INC. | $15.66 | 2020 | |
| Nabriva Therapeutics, Plc | $14.57 | 2021 | |
| Esperion Therapeutics, INC. | $13.69 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.